Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Jan;11(1):12-20.
doi: 10.1128/cdli.11.1.12-20.2004.

Magnitude of serum and intestinal antibody responses induced by sequential replicating and nonreplicating rotavirus vaccines in gnotobiotic pigs and correlation with protection

Affiliations

Magnitude of serum and intestinal antibody responses induced by sequential replicating and nonreplicating rotavirus vaccines in gnotobiotic pigs and correlation with protection

Marli S P Azevedo et al. Clin Diagn Lab Immunol. 2004 Jan.

Abstract

A sequential mucosal prime-boost vaccine regimen of oral attenuated (Att) human rotavirus (HRV) priming followed by intranasal (i.n.) boosting with rotavirus protein VP2 and VP6 rotavirus-like particles (2/6-VLPs) has previously been shown to be effective for induction of intestinal antibody-secreting cell (ASC) responses and protection in gnotobiotic pigs. Because serum or fecal antibody titers, but not intestinal ASC responses, can be used as potential markers of protective immunity in clinical vaccine trials, we determined the serum and intestinal antibody responses to this prime-boost rotavirus vaccine regimen and the correlations with protection. Gnotobiotic pigs were vaccinated with one of the two sequential vaccines: AttHRV orally preceding 2/6-VLP (VLP2x) vaccination (AttHRV/VLP2x) or following VLP2x vaccination (VLP2x/AttHRV) given i.n. with a mutant Escherichia coli heat-labile toxin (mLT) as adjuvant. These vaccines were also compared with three i.n. doses of VLP+mLT (VLP3x) and one and three oral doses of AttHRV (AttHRV1x and AttHRV3x, respectively). Before challenge all pigs in the AttHRV/VLP2x group seroconverted to positivity for serum immunoglobulin A (IgA) antibodies. The pigs in this group also had significantly higher (P < 0.05) intestinal IgA antibody titers pre- and postchallenge and IgG antibody titers postchallenge compared to those in the other groups. Statistical analyses of the correlations between serum IgM, IgA, IgG, and virus-neutralizing antibody titers and protection demonstrated that each of these was an indicator of protective immunity induced by the AttHRV3x and the AttHRV/VLP2x regimens. However, only IgA and not IgM or IgG antibody titers in serum were highly correlated (R2 = 0.89; P < 0.001) with the corresponding isotype antibody (IgA) titers in the intestines among all the vaccinated groups, indicating that the IgA antibody titer is probably the most reliable indicator of protection.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Seroconversion to positivity for isotype-specific and VN antibodies to HRV Wa in sera of gnotobiotic pigs inoculated with the different vaccine regimens. Arrows indicate the day of challenge. Symbols: ⧫, IgM; □, IgA; ▴, IgG, ×, VN antibody.
FIG. 2.
FIG. 2.
Titers of isotype-specific antibodies to HRV Wa in sera of gnotobiotic pigs inoculated with the different vaccine regimens. The error bars represent standard errors of the means. Lowercase letters denote significant differences (P < 0.05, by one-way ANOVA and Duncan's multiple-range test) among the vaccine and the control groups.
FIG. 3.
FIG. 3.
Titers of isotype-specific antibodies to HRV Wa in the intestinal contents of gnotobiotic pigs inoculated with the different vaccine regimens. The error bars represent standard errors of the means. Lowercase letters denote significant differences (P < 0.05 by one-way ANOVA and Duncan's multiple-range test) among the vaccine and the control groups.

References

    1. Barnes, G. L., J. S. Lund, S. V. Mitchell, L. De Bruyn, L. Piggford, A. L. Smith, J. Furmedge, P. J. Masendycz, H. C. Bugg, N. Bogdanovic-Sakran, J. B. Carlin, and R. F. Bishop. 2002. Early phase II trial of human rotavirus vaccine candidate RV3. Vaccine 20:2950-2956. - PubMed
    1. Bartlett, A. V., III, A. J. Bednarz-Prashad, H. L. DuPont, and L. K. Pickering. 1987. Rotavirus gastroenteritis. Annu. Rev. Med. 38:399-415. - PubMed
    1. Bohl, E. H., K. W. Theil, and L. J. Saif. 1984. Isolation and serotyping of porcine rotaviruses and antigenic comparison with other rotaviruses. J. Clin. Microbiol. 19:105-111. - PMC - PubMed
    1. Brandt, C. D., H. W. Kim, W. J. Rodriguez, J. O. Arrobio, B. C. Jeffries, E. P. Stallings, C. Lewis, A. J. Miles, R. M. Chanock, A. Z. Kapikian, and R. H. Parrott. 1983. Pediatric viral gastroenteritis during eight years of study. J. Clin. Microbiol. 18:71-78. - PMC - PubMed
    1. Brown, K. A., J. A. Kriss, C. A. Moser, W. J. Wenner, and P. A. Offit. 2000. Circulating rotavirus-specific antibody-secreting cells (ASCs) predict the presence of rotavirus-specific ASCs in the human small intestinal lamina propria. J. Infect. Dis. 182:1039-1043. - PubMed

Publication types

MeSH terms

LinkOut - more resources